Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nourishing kidney and activating blood (Bushen Huoxue) is a Traditional Chinese Medicine (TCM) therapeutic principle and the name of a specific granule formulation developed by Longhua Hospital, affiliated with the Shanghai University of Traditional Chinese Medicine. The formulation is primarily investigated for the treatment of primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis. It is a combination of two classic TCM formulas: Shixiao powder (Shi Xiao San), which is traditionally used to resolve blood stasis and alleviate pain, and Erzhi Pill (Er Zhi Wan), which is used to tonify the liver and kidney yin. In clinical trial contexts, such as ChiCTR1900026813, this granule is evaluated as an adjunctive therapy to ursodeoxycholic acid (UDCA) to assess its efficacy in improving biochemical markers, reducing liver fibrosis, and enhancing patient survival in PBC patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nourishing kidney and activating blood.